Nektar Therapeutics is a biopharmaceutical company developing medicines to address unmet medical needs worldwide, such as cancer and autoimmune disorders. Its products, including Bempegaldesleukin and NKTR-358, are in various stages of clinical trial for the treatment of melanoma, lung cancer, COVID-19, systemic lupus erythematosus, and ulcerative colitis. The company has formed collaboration agreements with several pharmaceuticals, including Bristol-Myers Squibb and Pfizer, and is headquartered in San Francisco.